- Home
- DSY vs KOD Comparison
DSY vs KOD Comparison
Compare DSY & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- KOD
- Stock Information
- Founded
- DSY 2020
- KOD 2009
- Country
- DSY China
- KOD United States
- Employees
- DSY N/A
- KOD N/A
- Industry
- DSY
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DSY
- KOD Health Care
- Exchange
- DSY Nasdaq
- KOD Nasdaq
- Market Cap
- DSY 194.1M
- KOD 186.3M
- IPO Year
- DSY N/A
- KOD 2018
- Fundamental
- Price
- DSY $2.32
- KOD $5.90
- Analyst Decision
- DSY
- KOD Hold
- Analyst Count
- DSY 0
- KOD 5
- Target Price
- DSY N/A
- KOD $3.50
- AVG Volume (30 Days)
- DSY 74.1K
- KOD 418.9K
- Earning Date
- DSY 12-03-2024
- KOD 11-26-2024
- Dividend Yield
- DSY N/A
- KOD N/A
- EPS Growth
- DSY N/A
- KOD N/A
- EPS
- DSY 11.99
- KOD N/A
- Revenue
- DSY $7,984,260.00
- KOD N/A
- Revenue This Year
- DSY N/A
- KOD N/A
- Revenue Next Year
- DSY N/A
- KOD N/A
- P/E Ratio
- DSY $0.19
- KOD N/A
- Revenue Growth
- DSY 224.34
- KOD N/A
- 52 Week Low
- DSY $0.75
- KOD $2.19
- 52 Week High
- DSY $13.47
- KOD $7.77
- Technical
- Relative Strength Index (RSI)
- DSY 39.68
- KOD 80.20
- Support Level
- DSY $2.17
- KOD $5.08
- Resistance Level
- DSY $2.80
- KOD $6.00
- Average True Range (ATR)
- DSY 0.48
- KOD 0.38
- MACD
- DSY -0.08
- KOD 0.06
- Stochastic Oscillator
- DSY 23.56
- KOD 94.14
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.